Targeted cancer therapy with ribosome biogenesis inhibitors: a real possibility?

Area of Science:

• Oncology and Molecular Biology
• Cancer Therapeutics

Background:

• Chemotherapeutic drugs' impact on ribosome biogenesis is often underestimated.
• Many DNA-damaging agents exert toxicity by inhibiting rRNA synthesis or maturation.
• Emerging cancer therapies target ribosome biogenesis without genotoxic activity.

Purpose of the Study:

• To review the characteristics of cancer cells that render them susceptible to ribosome biogenesis inhibitors.
• To explore the potential of selectively targeting ribosome biogenesis for cancer treatment.

Main Methods:

• Literature review of existing studies on ribosome biogenesis inhibitors in cancer therapy.
• Analysis of molecular mechanisms underlying cancer cell sensitivity to these inhibitors.

Main Results:

• Ribosome biogenesis inhibition is a significant mechanism of action for various chemotherapeutic drugs.
• Cancer cells exhibit heightened sensitivity to ribosome biogenesis inhibitors due to cell cycle dysregulation and oncogenic mutations.
• Selective inhibition of ribosome biogenesis can lead to targeted cancer cell damage.

Conclusions:

• Targeting ribosome biogenesis represents a promising strategy for cancer chemotherapy.
• Understanding cancer cell-specific vulnerabilities in ribosome biogenesis is crucial for developing effective and selective treatments.